Analysts Set DBV Technologies S.A. (NASDAQ:DBVT) Price Target at $38.65

DBV Technologies S.A. (NASDAQ:DBVT) has been given a consensus rating of “Moderate Buy” by the nine ratings firms that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has issued a hold recommendation, four have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $38.65.

Several equities analysts have recently commented on the stock. Citizens Jmp upped their price target on shares of DBV Technologies from $45.00 to $47.00 and gave the stock a “market outperform” rating in a research report on Friday, March 27th. Wall Street Zen lowered shares of DBV Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Weiss Ratings restated a “sell (e+)” rating on shares of DBV Technologies in a research report on Monday, December 29th. Finally, Guggenheim restated a “buy” rating and issued a $51.00 price target on shares of DBV Technologies in a research note on Friday, March 27th.

DBV Technologies Price Performance

NASDAQ:DBVT opened at $19.80 on Thursday. The firm has a market capitalization of $1.10 billion, a P/E ratio of -3.79 and a beta of -0.94. The business has a 50 day simple moving average of $20.90 and a 200 day simple moving average of $18.73. DBV Technologies has a 12-month low of $7.53 and a 12-month high of $26.18.

DBV Technologies (NASDAQ:DBVT) last issued its earnings results on Saturday, February 14th. The company reported ($1.15) earnings per share for the quarter. The company had revenue of $0.65 million during the quarter. DBV Technologies had a negative return on equity of 189.17% and a negative net margin of 2,606.83%. Research analysts anticipate that DBV Technologies will post -0.82 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of DBVT. Allworth Financial LP bought a new stake in shares of DBV Technologies during the fourth quarter valued at about $32,000. Royal Bank of Canada bought a new position in DBV Technologies in the 4th quarter valued at about $34,000. GAMMA Investing LLC grew its position in DBV Technologies by 38.4% in the 4th quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock valued at $51,000 after buying an additional 744 shares in the last quarter. New York State Common Retirement Fund acquired a new position in DBV Technologies during the 3rd quarter valued at about $34,000. Finally, Truvestments Capital LLC lifted its stake in shares of DBV Technologies by 71.3% in the 4th quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock worth $75,000 after acquiring an additional 1,620 shares during the period. Institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.